Allergan eyes billion-dollar mascara market

Move over mascara. Allergan announced today that it will be filing a new drug application for bimatoprost, a drug that it claims encourages eyelash growth. It expects sales in excess of $500 million per year--modest expectations in light of the estimated $3.7 billion per year mascara market. Allergan makes Lumigan, a glaucoma remedy that had the unusual added benefit of promoting eyelash growth. Some doctors were prescribing it off-lable for its cosmetic use, and Allergan has struck out at cosmetic companies for producing an OTC products they say are based partly on Lumigan ingredients.

Bimatoprost, a synthetic prostaglandin analog, results in eyelash growth that is significant when applied directly to the eyelash bases, according to Allergan's clinical trials. The company expects FDA to approve the drug in 2009.

- read the news in the WSJ
- s
ee MarketWatch for more

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.